Evidence map›Paper›PMID 34169631›Full record

ReviewVeterinary and comparative oncology2021

There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.

Samuel A Brill, Douglas H Thamm

Open access · bronzeAbstract readReview
In one paragraph

Review in Veterinary and comparative oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Samuel A BrillFlint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
Douglas H ThammFlint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.ORCID https://orcid.org/0000-0002-8914-7767
Colorado State University · USUniversity of Colorado Cancer Center · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Dual-Degree Medical Scientist Training Program for VeterinariansT32GM136628 · NIGMS · COLORADO STATE UNIVERSITY · PI ANNE C AVERY, Daniel Patrick Regan · 2020 to 2026
$1.9M
Neuromodulation for AsthmaU18TR001925 · NCATS · JOHNS HOPKINS UNIVERSITY · PI CANNING, BRENDAN J, KOLLARIK, MARIAN · 2016 to 2017
$1.0M
Dogs as a high fidelity, high throughput model to evaluate CAR-T cell function and dysfunctionF31CA265165 · NCI · COLORADO STATE UNIVERSITY · PI BRILL, SAMUEL · 2021 to 2025
$215k
Colorado Clinical and Translational Sciences Institute CO-C-19-25NCI NIH HHS F31 CA265165NCI NIH HHS P30 CA046934NIGMS NIH HHS 1-T32-GM-136628NIGMS NIH HHS T32 GM136628
6 · The paper itself

Abstract

Adoptive cell transfer (ACT) is a burgeoning therapeutic modality within human immuno-oncology. Novel approaches towards ACT are being developed in the pre-clinical setting faster than they can be evaluated in human clinical trials. Many of the therapeutic approaches used in human medicine have already been evaluated to some degree in canine patients. While this form of immunotherapy in veterinary medicine is still in its infancy, as these approaches develop, canine ACT will become a tool for both the veterinary oncologist and the translational researcher. This review details canine ACT trials to date, with attention given to the precedents provided by human oncology.

Indexed as

Cell- and Tissue-Based TherapyDog DiseasesImmunotherapyNeoplasmsAnimalsClinical Trials, Veterinary as TopicDogsHumansdogimmunotherapyoncology

Identifiers

PMID34169631
PMCPMC9310446
OpenAlexW3173923376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.